Significant class action cases involving different types of FDA-regulated products have been prevalent in the past several years. This webinar will discuss recent trends in class action litigation, including jurisdictions in which actions are most frequently filed, common claims theories, and settlement strategies. Speakers will also discuss how recent amendments to Rule 23 of the Federal Rules of Civil Procedure could affect litigation strategy, the evolving standard of ascertainability in addressing class certification, and damages models. Finally, we will look at the future of class actions for FDA-regulated products.
- +$100 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Anthony Anscombe, Partner, Steptoe & Johnson LLP
August Horvath, Partner, Foley Hoag LLP
William Janssen, Professor of Law, Charleston School of Law
Glenn Lammi, Chief Counsel, Legal Studies Division, Washington Legal Foundation